Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Risk of second primary hematological malignancy post chimeric antigen receptor T-cell therapy in diffuse large B-cell lymphoma: Propensity-matched analysis using trinetx database

View Full Paper
Ask AI
Bookmark
Share

Authors

JCJuhi ChovatiyaAMAqsa MunirNGNency Ganatra

Discussion

Loading...

Member takes

Overview

Analysis reveals significant association between CAR-T therapy and second primary malignancies in lymphoma, highlighting need for ongoing monitoring.

Key Points

  • CAR-T therapy is linked to a higher risk of second primary hematological malignancies, including MDS and AML.
  • In a cohort of 1,871 CAR-T patients, the incidence of myelodysplastic syndrome was 3.83% and acute myeloid leukemia was 3.17%.
  • Retrospective cohort analysis using TriNetX database assessed over 250 million patient records.
  • Long-term hematologic surveillance is necessary to mitigate risks associated with CAR-T treatment for DLBCL.

Cite This Study

Chovatiya et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d656https://doi.org/10.1182/blood-2025-1951
View Full Paper
Ask AI
Bookmark
Share